Cite
HARVARD Citation
Soria, J. et al. (n.d.). 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. European journal of cancer. pp. S637-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Soria, J. et al. (n.d.). 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. European journal of cancer. pp. S637-. [Online].